Overview & Approach
Muscular Dystrophy (MD) involves progressive muscle degeneration and loss of motor function. Our specialized center in India provides targeted cellular therapy utilizing autologous or compliant allogeneic mesenchymal stem cells (MSCs) combined with intensive neuro-rehabilitation.
Primary Objective
Primary Objective: Slow disease progression, preserve muscle tissue, and enhance day-to-day functional independence.
Biological Mechanism
Mechanism: Promote cellular signaling, reduce chronic muscle inflammation, and support tissue regeneration.
Patient Eligibility
Suitability is determined through a complimentary, remote review by our multidisciplinary medical board.
✓ Eligible Indications
Eligible Conditions: Duchenne (DMD), Becker (BMD), Limb-Girdle (LGMD), Facioscapulohumeral (FSHD), and related dystrophies.
• Clinical Criteria
Requirements: Confirmed genetic/clinical diagnosis, stable cardiac and pulmonary function, and medical clearance for international travel.
✗ Exclusion Criteria
Exclusions: Severe unmanaged systemic infections, critical organ failure, or active malignancies.
Potential Improvements Post-Therapy
Therapy outcomes vary based on disease stage and individual patient response. Expected functional gains include:
Why Choose Our Center in India?
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(inpatient package covering targeted ultrasound-guided intramuscular micro-injections + systemic IV infusion, CPK monitoring, and pulmonary assessments).
(Administered via Targeted Intramuscular + Systemic IV under strict cGMP lab standards).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated International Patient Services
We provide end-to-end support to ensure a seamless medical journey:
Logistics & Accommodation
Typical Treatment Schedule (7–10 Days)
Our streamlined protocol minimizes travel downtime while maximizing clinical oversight:
Source Distinctions & Donor Screening Rigor
Autologous Cells
Autologous Cells: Harvested from the patient’s own bone marrow or adipose tissue; eliminates foreign immunological reactions but requires an invasive collection procedure.
Allogeneic Umbilical Cord Tissue
Allogeneic Umbilical Cord Tissue: Screened donor tissue processed in ISO Class 5 cleanrooms.
Mandatory Donor Safety Testing
Mandatory Donor Safety Testing: Every donor batch undergoes mandatory molecular screening for HIV 1 & 2, Hepatitis B (HBV), Hepatitis C (HCV), Syphilis (VDRL), Cytomegalovirus (CMV), and Human T-lymphotropic virus (HTLV 1/2).
Cellular Quality Release Standards
Cellular Quality Release: Documented post-thaw viability exceeding 90%, sterility cultures (zero bacterial/fungal growth), and negative endotoxin testing (LAL test).
Frequently Asked Questions: Muscular Dystrophy Care
Evidence-based clinical guidance regarding cellular protocols, anticipated outcomes, and international logistics
No. Muscular dystrophy is an inherited genetic condition. Stem cell therapy serves as an adjuvant cellular therapy that aims to slow muscle degeneration, reduce chronic fibrosis, and activate dormant muscle satellite cells to preserve functional independence (Cossu et al., 2015).
Centers evaluate Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), and Facioscapulohumeral Dystrophy (FSHD).
Monitoring incorporates North Star Ambulatory Assessment (NSAA) scores, 6-minute walk distance (6MWD), serum Creatine Phosphokinase (CPK) enzyme reductions, and pulmonary Forced Vital Capacity (FVC).
Treatment combines systemic intravenous infusion with high-precision ultrasound-guided intramuscular micro-injections into key functional muscle groups (e.g., quadriceps, biceps, deltoids).
Gentle, non-exhausting physical therapy, aquatic hydrotherapy, and assisted stretching are integral to maintain range of motion and maximize muscular assimilation.
The complete clinical pathway requires 4 to 5 days in India, accommodating pre-procedure pulmonary/cardiac clearance, cellular administration, post-procedure monitoring, and travel fitness certification.
Peer-Reviewed Scientific Citations & Clinical References
Key published clinical trials and peer-reviewed literature supporting cellular therapy in Muscular Dystrophy: